⚠️ Small Study / Early Comparative Evidence
Researchers examined whether extended aldosterone synthase inhibition (EASI) produced sustained effects after treatment stopped in people with primary aldosteronism. The study followed 14 participants treated at eight US centers after a six- to 12-month medication course. Routine follow-up measurements showed persistent suppression of excess aldosterone production and partial or complete resolution of hypertension for up to two years. The findings were published in the New England Journal of Medicine.
Clinical Considerations
- The main marker of excess aldosterone production remained 99% lower than before treatment, while blood pressure averaged 25 points lower.
- Almost a quarter of participants had normal blood pressure without taking any other medication.
- Hormone levels and blood pressure remained similar to, or lower than, levels recorded during EASI treatment.
- Earlier hypertension studies generally assessed six- to 12-week treatment courses, with outcomes measured while participants were taking medication.
- The lead author expressed caution because of the study’s pragmatic nature and stated that longer follow-up could clarify whether remission represents cure.
Practice Applications
- The researchers describe finite medication treatment as a possible alternative to lifelong therapy or adrenal surgery for some people with primary aldosteronism.
- The lead author stated that EASI is unlikely to offer this possibility for most people with hypertension.
- The prospective ELIXIR trial will investigate lasting remission and use molecular imaging to examine whether prolonged treatment causes aldosterone-producing cells to disappear.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS